Day: October 18, 2025

Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care endocrine therapy plus everolimus1 The giredestrant combination was well tolerated; no new safety signals were observed including no photopsia1 Overall survival data were immature, but a clear positive trend was seen in both the ITT and ESR1-mutated populations1 If approved, giredestrant plus everolimus could be the first and only oral selective oestrogen receptor degrader combination in the post-CDK inhibitor settingBasel, 18 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III evERA Breast Cancer study. Data showed giredestrant in combination with everolimus significantly...

FUKUOKA, Japan, Oct. 17, 2025 (GLOBE NEWSWIRE) — rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, announced a series of strategic corporate developments and global partnerships to expand its legal consulting and osteopathic clinic services on an international scale. Earlier this month, Company CEO Ryoji Baba was officially invited by the Embassy of Japan in Vietnam and appointed as a Board Member of United Nations-affiliated non-governmental organization (“NGO”) Koyamada International Foundation (“KIF”) and its affiliated organization, Guardian Girls International (“GGI”). KIF is an international NGO dedicated to promoting global peace, sustainable development, and improving quality of life through humanitarian, educational, and empowerment programs. Its initiatives...